141 related articles for article (PubMed ID: 37918656)
41. Factors related to central nervous system involvement of primary vitreoretinal lymphoma.
Kim JY; Kim JJ; Kim RY; Kim M; Park YG; Park YH
Graefes Arch Clin Exp Ophthalmol; 2024 Mar; ():. PubMed ID: 38446203
[TBL] [Abstract][Full Text] [Related]
42. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H; Chevrier M; Laadhari M; Chinot O; Choquet S; Moluçon-Chabrot C; Beauchesne P; Gressin R; Morschhauser F; Schmitt A; Gyan E; Hoang-Xuan K; Nicolas-Virelizier E; Cassoux N; Touitou V; Le Garff-Tavernier M; Savignoni A; Turbiez I; Soumelis V; Houillier C; Soussain C
Ann Oncol; 2019 Apr; 30(4):621-628. PubMed ID: 30698644
[TBL] [Abstract][Full Text] [Related]
43. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.
Akpek EK; Ahmed I; Hochberg FH; Soheilian M; Dryja TP; Jakobiec FA; Foster CS
Ophthalmology; 1999 Sep; 106(9):1805-10. PubMed ID: 10485554
[TBL] [Abstract][Full Text] [Related]
44. Clinical Outcomes in Vitrectomized versus Non-vitrectomized Eyes in Patients with Primary Vitreoretinal Lymphoma.
Liberman P; Francis JH; Mehrotra K; Tian J; McGarrey MP; Sobol EK; Thorne JE; Aronow ME; Berkenstock MK
Ocul Immunol Inflamm; 2023 Apr; 31(3):496-500. PubMed ID: 35201943
[TBL] [Abstract][Full Text] [Related]
45. An unusual case report of primary vitreoretinal lymphoma.
Tan SZ; Steeples LR; Chhabra R; Jones NP
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):223. PubMed ID: 30255824
[TBL] [Abstract][Full Text] [Related]
46. [Primary vitreoretinal lymphoma].
Jaehne D; Coupland SE
Ophthalmologe; 2018 Apr; 115(4):343-356. PubMed ID: 29589147
[TBL] [Abstract][Full Text] [Related]
47. CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS.
Liu S; Gu J; Zhang T; Ping B; Zhou M; Huang X; Jiang R; Xu G; Chang Q
Retina; 2021 Dec; 41(12):2596-2604. PubMed ID: 34173362
[TBL] [Abstract][Full Text] [Related]
48. Two cases of primary vitreoretinal lymphoma: a diagnostic challenge : The supporting role of multimodal imaging in the diagnosis of primary vitreoretinal lymphoma.
Morara M; Foschi F; Veronese C; Torrazza C; Bacci F; Stefoni V; Ciardella PA
Int Ophthalmol; 2018 Feb; 38(1):353-361. PubMed ID: 28039672
[TBL] [Abstract][Full Text] [Related]
49. Recurrent pseudohypopyon in association with primary vitreoretinal lymphoma: a case report.
Kitao M; Hashida N; Nishida K
BMC Ophthalmol; 2016 Jul; 16():103. PubMed ID: 27391815
[TBL] [Abstract][Full Text] [Related]
50. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
Demirci H; Rao RC; Elner VM; Demirci FY; Axenov L; Betz B; Behdad A; Brown N
Ophthalmol Retina; 2023 Feb; 7(2):189-195. PubMed ID: 35952929
[TBL] [Abstract][Full Text] [Related]
51. Intraocular lymphoma: a clinical perspective.
Davis JL
Eye (Lond); 2013 Feb; 27(2):153-62. PubMed ID: 23196650
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal Analysis of Ocular Manifestation and Interleukin During Intravitreal Treatment of Vitreoretinal Lymphoma With Methotrexate.
Gu J; Jiang T; Liu S; Chen X; Wang Z; Zhang P; Wang L; Jiang R; Huang X; Xu G; Chang Q
Am J Ophthalmol; 2023 Jul; 251():189-196. PubMed ID: 36963600
[TBL] [Abstract][Full Text] [Related]
53. Primary vitreoretinal lymphoma: prevalence, impact, and management challenges.
Venkatesh R; Bavaharan B; Mahendradas P; Yadav NK
Clin Ophthalmol; 2019; 13():353-364. PubMed ID: 30858685
[TBL] [Abstract][Full Text] [Related]
54. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.
Yonese I; Takase H; Yoshimori M; Onozawa E; Tsuzura A; Miki T; Mochizuki M; Miura O; Arai A
Eur J Haematol; 2019 Feb; 102(2):191-196. PubMed ID: 30390359
[TBL] [Abstract][Full Text] [Related]
55. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate.
Zhao H; Wang X; Mao Y; Peng X
BMC Ophthalmol; 2020 Jan; 20(1):10. PubMed ID: 31906917
[TBL] [Abstract][Full Text] [Related]
56. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma.
Chan CC; Sen HN
Discov Med; 2013 Feb; 15(81):93-100. PubMed ID: 23449111
[TBL] [Abstract][Full Text] [Related]
57. A diagnostic challenge of primary Central nervous system lymphoma: from the eyes to the brain.
Su M; Huang D; Sun L; Dong Z; Wu L; Yu S
Int J Neurosci; 2021 Nov; 131(11):1139-1145. PubMed ID: 32449877
[TBL] [Abstract][Full Text] [Related]
58. Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514).
Soussain C; Malaise D; Choquet S; Ghesquières H; Houillier C
Eur J Cancer; 2023 Aug; 189():112909. PubMed ID: 37301714
[No Abstract] [Full Text] [Related]
59. Clinical Features Predictive of Survival in Patients With Vitreoretinal Lymphoma: Analysis of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Porcu P; Martinez NL; Glass J; Mashayekhi A; Shields CL
Asia Pac J Ophthalmol (Phila); 2020; 9(2):110-116. PubMed ID: 31923035
[TBL] [Abstract][Full Text] [Related]
60. Multimodal imaging characteristics in eyes with vitreoretinal lymphoma treated with intravitreal rituximab.
Rishi P; Maitra P; Das K; Rishi E; Manchegowda PT
Int Ophthalmol; 2021 Aug; 41(8):2711-2722. PubMed ID: 33834345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
